EGFR and non-small cell lung carcinoma: Recent developments in NSCLC therapies that specifically target driver oncogenes, such as epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-sensitizing mutations, have changed the standard of care and prognosis for patients with advanced NSCLC7–10.